Entropy Technologies LP Purchases Shares of 7,297 Smith & Nephew SNATS, Inc. (NYSE:SNN)

Key Points

• Entropy Technologies LP acquired 7,297 shares of Smith & Nephew SNATS, Inc., valuing the investment at approximately $207,000.
• Smith & Nephew recently declared a semi-annual dividend of $0.285 per share, with a dividend yield of 210.0% and a dividend payout ratio of 41.20%.
• Investment analysts have generally rated Smith & Nephew with a "Hold" rating, with an average price target set at $28.00.

Entropy Technologies LP purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,297 shares of the medical equipment provider's stock, valued at approximately $207,000.

Several other hedge funds also recently added to or reduced their stakes in SNN. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Smith & Nephew SNATS by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,281 shares of the medical equipment provider's stock worth $434,000 after acquiring an additional 672 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Smith & Nephew SNATS by 7.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 35,890 shares of the medical equipment provider's stock worth $1,018,000 after acquiring an additional 2,585 shares during the last quarter. Cary Street Partners Financial LLC purchased a new position in shares of Smith & Nephew SNATS during the first quarter worth approximately $547,000. PNC Financial Services Group Inc. grew its position in shares of Smith & Nephew SNATS by 8.8% during the first quarter. PNC Financial Services Group Inc. now owns 9,923 shares of the medical equipment provider's stock worth $282,000 after acquiring an additional 803 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of Smith & Nephew SNATS by 19.8% during the first quarter. US Bancorp DE now owns 16,299 shares of the medical equipment provider's stock worth $462,000 after acquiring an additional 2,695 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN opened at $36.20 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The stock has a fifty day moving average price of $31.24 and a 200 day moving average price of $28.82. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $36.84. The company has a market cap of $15.85 billion, a PE ratio of 16.76, a P/E/G ratio of 1.01 and a beta of 0.68.

Smith & Nephew SNATS Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be issued a dividend of $0.285 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's dividend payout ratio (DPR) is currently 41.20%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research report on Thursday, May 1st. HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Hsbc Global Res downgraded Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $28.00.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.